4D-150 Gene Therapy Shows 87% Injection Reduction in Wet AMD at 2 Years
FDMT has more than doubled off its 52-week low of $4.145.
Summary
Two-year data from the PRISM Phase 2b trial of 4D-150 in wet AMD show durable efficacy and safety. In the recently diagnosed subgroup, patients needed only 1.6 mean supplemental injections over two years versus 12 projected with standard aflibercept, an 87% reduction. Visual acuity and retinal anatomy remained stable. 4D-150 continues to be well tolerated with no new safety findings, and no new inflammation after 28 weeks in 71 patients across Phase 1/2a and 2b. The data were presented at ASRS 2026, directly supporting the ongoing 4FRONT Phase 3 program. With a $575M market cap, positive Phase 3 results would be transformative, and the next major catalyst is Phase 3 enrollment completion and eventual data readout.
At the time of this announcement, FDMT was trading at $10.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $574.5M. The 52-week trading range was $4.15 to $14.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.